Zai Lab's stock soared 5.52% during intraday trading on Friday, following the release of better-than-expected quarterly results and the announcement of upcoming commercial plans.

The pharmaceutical company reported a quarterly adjusted loss of 5 cents per share for the quarter ended December 31, beating analyst estimates of a 6 cent loss. Revenue also exceeded expectations, rising 17.1% year-over-year to $127.09 million compared to estimates of $124.47 million.

Investors responded positively to the earnings beat and the company's announcement of plans for the commercial launch of KarXT in the first half of 2026. Analyst sentiment remains bullish with a "buy" rating and a median 12-month price target of HK$22.46, representing approximately 35.5% upside from the previous closing price.